Phase I Clinical Trial Using [99mTc]Tc-1-thio-D-glucose for Diagnosis of Lymphoma Patients
| Parent link: | Pharmaceutics.— .— Basel: MDPI AG Vol. 14, iss. 6.— 2022.— Article number 1274, 12 p. |
|---|---|
| Autor corporatiu: | |
| Altres autors: | , , , , , , , , , |
| Sumari: | Similar to [18F]-FDG, [99mTc]Tc-1-thio-D-glucose ([99mTc]Tc-TG) also binds to GLUT receptors. The aim of this Phase I study was to evaluate the safety, biodistribution and dosimetry of [99mTc]Tc-TG. Twelve lymphoma patients were injected with 729 ± 102 MBq [99mTc]Tc-TG. Wholebody planar imaging was performed in 10 patients at 2, 4, 6 and 24 h after injection. In all 12 patients,
SPECT/CT (at 2 h) and SPECT (at 4 and 6 h) imaging was performed. Vital signs and possible side effects were monitored during imaging and up to 7 days after injection. [99mTc]Tc-TG injections were well-tolerated and no side effects or alterations in blood and urine analyses data were observed.
The highest absorbed dose was in the kidneys and urinary bladder wall, followed by the adrenals, prostate, bone marrow, lungs, myocardium, ovaries, uterus, liver and gall bladder wall. [99mTc]TcTG SPECT/CT revealed foci of high activity uptake in the lymph nodes of all nine patients with known nodal lesions. Extranodal lesions were detected in all nine cases. In one patient, a lesion in
the humerus head, which was not detected by CT, was visualized using [99mTc]Tc-TG. Potentially, [99mTc]Tc-TG can be considered as an additional diagnostic method for imaging GLUT receptors in lymphoma patients.
Текстовый файл |
| Idioma: | anglès |
| Publicat: |
2022
|
| Matèries: | |
| Accés en línia: | https://doi.org/10.3390/pharmaceutics14061274 |
| Format: | Electrònic Capítol de llibre |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=672838 |
MARC
| LEADER | 00000naa0a2200000 4500 | ||
|---|---|---|---|
| 001 | 672838 | ||
| 005 | 20251204155319.0 | ||
| 014 | |2 sici | ||
| 090 | |a 672838 | ||
| 100 | |a 20240529d2023 k||y0rusy50 ba | ||
| 101 | 1 | |a eng |c rus | |
| 102 | |a CH | ||
| 135 | |a drcn ---uucaa | ||
| 181 | 0 | |a a |b e | |
| 182 | 0 | |a b | |
| 183 | 0 | |a cr |2 RDAcarrier | |
| 200 | 1 | |a Phase I Clinical Trial Using [99mTc]Tc-1-thio-D-glucose for Diagnosis of Lymphoma Patients |f V. Chernov, E. Dudnikova, R. Zelchan [et al.] |d Фаза I клинического испытания с использованием [99mTc] Tc-1-тио-D-глюкозы для диагностики пациентов с лимфомой |z rus | |
| 203 | |a Текст |b визуальный |c электронный | ||
| 283 | |a online_resource |2 RDAcarrier | ||
| 320 | |a References: p. 11-12 (23 tit.) | ||
| 330 | |a Similar to [18F]-FDG, [99mTc]Tc-1-thio-D-glucose ([99mTc]Tc-TG) also binds to GLUT receptors. The aim of this Phase I study was to evaluate the safety, biodistribution and dosimetry of [99mTc]Tc-TG. Twelve lymphoma patients were injected with 729 ± 102 MBq [99mTc]Tc-TG. Wholebody planar imaging was performed in 10 patients at 2, 4, 6 and 24 h after injection. In all 12 patients, SPECT/CT (at 2 h) and SPECT (at 4 and 6 h) imaging was performed. Vital signs and possible side effects were monitored during imaging and up to 7 days after injection. [99mTc]Tc-TG injections were well-tolerated and no side effects or alterations in blood and urine analyses data were observed. The highest absorbed dose was in the kidneys and urinary bladder wall, followed by the adrenals, prostate, bone marrow, lungs, myocardium, ovaries, uterus, liver and gall bladder wall. [99mTc]TcTG SPECT/CT revealed foci of high activity uptake in the lymph nodes of all nine patients with known nodal lesions. Extranodal lesions were detected in all nine cases. In one patient, a lesion in the humerus head, which was not detected by CT, was visualized using [99mTc]Tc-TG. Potentially, [99mTc]Tc-TG can be considered as an additional diagnostic method for imaging GLUT receptors in lymphoma patients. | ||
| 336 | |a Текстовый файл | ||
| 461 | 1 | |c Basel |n MDPI AG |t Pharmaceutics | |
| 463 | 1 | |d 2022 |t Vol. 14, iss. 6 |v Article number 1274, 12 p. | |
| 610 | 1 | |a [99mTc]Tc-1-thio-D-glucose | |
| 610 | 1 | |a single-photon emission computed tomography | |
| 610 | 1 | |a lymphoma | |
| 610 | 1 | |a Hodgkin’s lymphoma | |
| 610 | 1 | |a non-Hodgkin’s lymphomas | |
| 610 | 1 | |a труды учёных ТПУ | |
| 610 | 1 | |a электронный ресурс | |
| 701 | 1 | |a Chernov |b V. I. |c specialist in the field of medical technology |c lead engineer of Tomsk Polytechnic University, doctor of medical sciences |f 1962- |g Vladimir Ivanovich |9 17725 | |
| 701 | |a Dudnikova |b E. A. |g Ekaterina Aleksandrovna | ||
| 701 | 1 | |a Zelchan (Zeltchan) |b R. V. |c specialist in the field of medical technology |c Researcher of the Tomsk Polytechnic University, Candidate of Medical Sciences |f 1984- |g Roman Vladimirovich |9 17728 | |
| 701 | 1 | |a Medvedeva |b А. А. |g Anna Aleksandrovna |f 1975- |c specialist in the field of medical technology |c research fellow of Tomsk Polytechnic University, Doctor of Medical Sciences |y Tomsk |9 20294 | |
| 701 | 1 | |a Rybina |b A. N. |g Anastasiya Nikolaevna |f 1982- |c specialist in the field of biophysics |c Researcher of Tomsk Polytechnic University, Candidateof medical Sciences |y Tomsk |9 88810 | |
| 701 | 1 | |a Bragina |b O. D. |c specialist in the field of medical technology |c Senior Researcher of the Tomsk Polytechnic University, Doctor of Medical Sciences |f 1986- |g Olga Dmitrievna |y Tomsk |9 19084 | |
| 701 | 1 | |a Goldberg |b V. |g Victor | |
| 701 | 1 | |a Muravleva |b A. |g Albina | |
| 701 | 1 | |a Sorensen |b J. |g Jens | |
| 701 | 1 | |a Tolmachev |b V. M. |c specialist in the field of medical technology |c Director of the Research Center "Oncoteranostika", Tomsk Polytechnic University, Ph.D |f 1961- |g Vladimir Maksimilianovich |9 22210 | |
| 712 | 0 | 2 | |a National Research Tomsk Polytechnic University |c (2009- ) |9 27197 |
| 801 | 0 | |a RU |b 63413507 |c 20240529 | |
| 850 | |a 63413507 | ||
| 856 | 4 | |u https://doi.org/10.3390/pharmaceutics14061274 |z https://doi.org/10.3390/pharmaceutics14061274 | |
| 942 | |c CF | ||